Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
An article from
News roundup
Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
Published Aug. 7, 2026
Getty Images
Revolution Medicines eyes launch of daraxonrasib for pancreatic cancer awaiting US/EU approval, while advancing zoldonrasib &…
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis…
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's…
Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3…
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory…
